Results 101 to 110 of about 38,738 (212)
BiomoleculesGlucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United States Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes mellitus (T2DM) and obesity.
Katherine O. Kopp +4 more
doaj +1 more source
Integrating the inputs that shape pancreatic islet hormone release. [PDF]
, 2019 The pancreatic islet is a complex mini organ composed of a variety of endocrine cells and their support cells, which together tightly control blood glucose homeostasis.
Huising, Mark O, Noguchi, Glyn M
core
iScienceSummary: High glucose has been proved to impair cognitive function in type 2 diabetes, but the underlying mechanisms remain elusive. Here, we found that high glucose increased transcription factors’ SP1 O-GlcNAcylation in regulatory T (Treg) cells ...
Ya Hui +5 more
doaj +1 more source
Pediatric Obesity: Influence on Drug Dosing and Therapeutics [PDF]
, 2018 Obesity is an ongoing global health concern and has only recently been recognized as a chronic disease of energy homeostasis and fuel partitioning. Obesity afflicts 17% of US children and adolescents.
Ameer, Barbara, PharmD, MBA, BCPS, FCP +1 more
core +1 more source
Survodutide - Novel Anti Obesity Drug
JK ScienceSurvodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity.
Irtiqa Ayani Rathore +4 more
doaj
Advances in the treatment of type 2 diabetes: impact of dulaglutide
Diabetes, Metabolic Syndrome and Obesity, 2016 Angela M Thompson, Jennifer M TrujilloDepartment of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA Abstract: The purpose of this review is to provide a review of current data of the most ...
Thompson AM, Trujillo JM
doaj
GLP-1 receptor agonists, CKD, and eGFR trajectory [PDF]
The Lancet Diabetes & Endocrinology, 2018 van Baar, Michaël J. B. +2 more
openaire +4 more sources
Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025). [PDF]
CureusMakkena HB.
europepmc +1 more source
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications. [PDF]
Curr Obes RepLee J, You JH, Park HJ, Roh JL, Paek SH.
europepmc +1 more source
Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis. [PDF]
J Diabetes Metab DisordKamel-Abusalha L +6 more
europepmc +1 more source